FDA Clears Bracco’s New Ultrasound Contrast Delivery System for Cardiovascular Imaging

Ventripoint Expands Subscription Access for FDA-Cleared AI Cardiac Imaging

Commercial initiative aims to make VMS+ easier for hospitals to evaluate and adopt TORONTO, Aug. 12, 2026 (GLOBE NEWSWIRE) — Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV: VPT; OTC: VPTDF), a leader in AI-assisted cardiac imaging, today announced the next phase of its commercial strategy for VMS+™ 4.0, its FDA-cleared platform that turns standard heart-ultrasound […]

FDA clears Bracco’s new ultrasound contrast delivery system for cardiovascular imaging

The VueJect ultrasound contrast delivery system was designed to improve workflow efficiency and provide consistency from one user to the next.

Bracco VueJect Ultrasound Contrast Delivery System Receives FDA Clearance, Health Canada Authorization

August 12, 2026—Bracco Imaging announced United States FDA 510(k) clearance and Health Canada authorization for VueJect, the company’s ultrasound contrast delivery system designed to support cardiology imaging. According to the company, VueJect will initially be available in the United States and Canada. Additional regulatory submissions are planned in other markets as part of the company’s broader global commercialization strategy for VueJect, …

Bracco's VueJect contrast system secures FDA and Health Canada approvals

Bracco Imaging has obtained 510(k) clearance from the FDA and Health Canada authorisation for the VueJect contrast delivery system.The post Bracco’s VueJect contrast system secures FDA and Health Canada approvals appeared first on Hospital Management.

Contrast Media Market Outlook: Advancing Medical Imaging Solutions

Open the article to view the coverage from Daily Investor Hub